We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: May 18, 2006
Last Update Posted: August 11, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AmpliMed Corporation
AMP-007 is a Phase 1/2 study for the treatment of advanced, previously treated multiple myeloma. The first phase of the study is designed to determine a safe dose of imexon that can be given to patients with advanced, previously-treated multiple myeloma. The Phase 2 part of the study is designed to provide additional safety data and to gain an understanding of whether imexon can improve the outcome for patients with multiple myeloma

Condition Intervention Phase
Multiple Myeloma Drug: imexon Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) for Patients With Previously Treated Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by AmpliMed Corporation:

Primary Outcome Measures:
  • Determine the maximally tolerated dose of imexon in multiple myeloma patients
  • evaluate the toxicity of imexon
  • Preliminarily evaluate efficacy in terms of response and progression free survival.

Secondary Outcome Measures:
  • Evaluate biomarker responses.

Study Start Date: October 2005
Study Completion Date: January 2008
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Advanced myeloma, with measurable disease as defined in the protocol.
  • Prior treatment, at least 2 prior regimens are required. This may include prior treatment with investigational products.
  • Able to perform the activities of daily living.
  • Off prior therapy for at least 2-4 weeks depending on the drug.
  • Blood counts and blood chemistries in or near normal range.
  • If female, neither pregnant nor nursing.
  • Willing to use contraceptives to prevent pregnancy.
  • No other serious illnesses.
  • No other active malignancy.
  • No serious infections.
  • No current other drug therapy for the myeloma except for steroid therapy under certain circumstances. Biphosphonate therapy is permitted.
  • Prior radiation is permitted.

Exclusion Criteria:

  • Use of corticosteroids for amyloid disorders, or high dose chronic steroids.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00327249

United States, Arkansas
Investigational Site 025
Little Rock, Arkansas, United States, 72206
United States, Texas
Investigational Site 008
Houston, Texas, United States, 77030
Sponsors and Collaborators
AmpliMed Corporation
  More Information

Responsible Party: Evan Hersh, AmpliMed
ClinicalTrials.gov Identifier: NCT00327249     History of Changes
Other Study ID Numbers: AMP-007
First Submitted: May 17, 2006
First Posted: May 18, 2006
Last Update Posted: August 11, 2009
Last Verified: August 2009

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases